Printer Friendly
The Free Library
14,693,900 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Takeda Pharmaceutical, Hitachi Jointly Establish New Information System Company for Medical and Pharmaceutical Businesses.


Tokyo, Japan, Feb 20, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Takeda Pharmaceutical and Hitachi jointly announced February 20 the establishment of Hitachi Inspharma, Ltd., a joint venture to support and develop information systems for the medical and pharmaceutical industries.

Capitalized at 225 million yen ($1.9 mil An Internet address domain name for a military agency. See Internet address.

(networking) mil - The top-level domain for entities affiliated with US armed forces.
), Hitachi Inspharma will initially provide outsourcing (1) Contracting with outside consultants, software houses or service bureaus to perform systems analysis, programming and datacenter operations. Contrast with insourcing. See netsourcing, ASP, SSP and facilities management.  services to Takeda Pharmaceutical. Hitachi retains a 66% stake in the new company while Takeda Pharmaceutical holds the remaining 34%.

Upon expiration of the two-year joint venture period, the newly-established company will become a wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 of Hitachi. Hitachi Inspharma aims to generate approximately 4 billion yen ($33.8 mil) in sales in fiscal 2006.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 21, 2006
Words:115
Previous Article:Matsushita Electric Industrial Develops Compact Multichannel Biosensing Device.
Next Article:MEDINET, Yokohama City University, Shin-Yokohama Medical Clinic Jointly Launch Clinical Study of Immune Cell Therapy for Pancreatic Cancer.



Related Articles
Takeda Pharmaceutical, Santhera Pharmaceuticals to Collaborate to Develop and Commercialize Idebenone, Drug Candidate for Friedreich's Ataxia.
Hitachi, Takeda Pharmaceutical to Establish Information System Service Joint Venture.
Takeda Pharmaceutical Transfers All BASF Takeda Vitamin Shares to BASF Japan.
Dainippon Sumitomo Pharma, ASKA Pharmaceutical to Dissolve Dealing Contract.
FDA Approves AMITIZA, Chronic Idiopathic Constipation Agent - Sucampo and Takeda Pharmaceuticals to Begin Joint Promotion in Spring.
Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.
US District Court Dismisses Abbott Laboratories' Litigation Against Takeda Pharmaceutical.
Takeda Pharmaceutical to Establish New Sales and Marketing Company in London.
Takeda Announces Start of Phase 3 Clinical Program in the U.S.of Fixed Dose Combination Product of Actos(R) + TAK-536for Treatment of Patients with...
London Symphony Orchestra and Takeda Pharmaceutical Company Launch the 7th Takeda Global Concert Series.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles